Crystagen

Overview

Crystagen is a Khavinson bioregulator tripeptide (EDP) identified in thymalin with selective action on thymus tissues. Developed at Russia’s St. Petersburg Institute of Bioregulation and Gerontology, it enhances immune function by stimulating normal lymphocyte proliferation while inhibiting tumor cell growth. Research shows effectiveness in normalizing immunity in 82% of elderly patients (vs 56% control) and reducing respiratory infections in athletes by doubling HSP gene expression.

Mechanism of action

Crystagen works through epigenetic regulation by influencing gene expression and protein synthesis in immune cells. It regulates the synthesis of heat-shock proteins, cytokines, and affects cell differentiation, proliferation, and apoptosis. The EDP peptide enhances spontaneous proliferative activity of normal lymphocytes while inhibiting proliferation of tumor cells (K-562 erythromyelosis). It activates B-cell immune system and thymic epithelial cells (VTEC2.H/S).

Key research findings

• Normalizes immune function in 82% of patients
• Stimulates normal lymphocyte proliferation
• Inhibits tumor cell growth (antitumor activity)
• Doubles HSP gene expression (stress resistance)
• Reduces respiratory viral infections
• Activates B-cell immune system
• Normalizes IL-6 expression
• Effective after radiation/chemotherapy

Research applications

Immune Support

• Immune Dysfunction — Normalizes immunogram in elderly patients with impaired immunity.
• Post-Infection Recovery — Restores immune function after infectious diseases.
• Radiation/Chemo Recovery — Helps normalize immunity after radiation and chemotherapy exposure.

Stress Resistance

• Athletic Immune Support — Increases stress resistance and reduces respiratory infections in athletes.
• HSP Expression — Doubles expression of heat-shock protein gene HSPA1A.

Anti-Tumor

• Tumor Cell Inhibition — Inhibits proliferation of K-562 human erythromyelosis tumor cells.